48 search results for: quality of life

expert video

Can Emerging Treatments Help Address Individual PN Patient Burden?

17 min

Dermatology

Prof. Sonja Ständer emphasizes the high patient burden of PN, and how this is influenced by patient needs and comorbidities. She discusses how emerging treatments are reducing patient burden.

The Evolving Understanding <b>of</b> Prurigo Nodularis (PN) Has Implications for Patient Management

Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

5 min

Dermatology

An infographic summarizing the clinical manifestations and pathophysiological processes of PN.

expert video

Expert Interview: Featuring Dr Shawn Kwatra on PN itch and impact on patients

2 min

Dermatology

Join Dr Kwatra as he dives deeper into the mechanism of lesion formation in Prurigo Nodularis and the impact the development of these skin lesions have on patient life.

Why did the definition <b>of</b> control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

5 min

Rhinology

Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.

interactivity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

5 min

Pulmonology

Learn about the disease burden and heterogeneity of chronic obstructive pulmonary disease (COPD).

expert video

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

2 min

Dermatology

Dr. Chovatiya discusses the neuroinflammatory mechanisms of PN.

Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

15 min

Rhinology

Profs. Wytske Fokkens and Joaquim Mullol discuss the clinical significance of the loss of smell in patients with CRSwNP.

Tools for Clinical Assessment <b>of</b> Prurigo Nodularis

Infographic

Tools for Clinical Assessment of Prurigo Nodularis

17 min

Dermatology

An interactive guide that provides users with an overview of key assessment tools for Prurigo Nodularis clinical practice. Implementation of the most applied tools is exemplified via a patient case.

What Drives PN Disease? Exploring the Complexity <b>of</b> PN Pathophysiology

expert video

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology

15 min

Dermatology

Dr. Brian Kim discusses the numerous contributors to PN pathophysiology, including type 2 inflammation, neuronal dysfunction, and dermal fibrosis, emphasizing the unique and overlapping roles of IL 31, IL-4 and IL-13 in its pathology.

ERS 2024 | Understanding the Complex Pathophysiology <b>of</b> COPD

expert video

ERS 2024 | Understanding the Complex Pathophysiology of COPD

6 min

Pulmonology

Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.

How Can We Explore the Concept <b>of</b> Disease Modification in Children With AD?

expert video

How Can We Explore the Concept of Disease Modification in Children With AD?

2 min

Dermatology

Dr. Lawrence Eichenfield discusses the concept of disease modification in children with AD.

How Can FeNO Support the Management <b>of</b> Pediatric Asthma?

expert video

How Can FeNO Support the Management of Pediatric Asthma?

2 min

Pulmonology

Dr. Michael Blaiss discusses the importance of measuring FeNO in pediatric asthma patients.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: JapanChange country/region